Title: Basiliximab
CAS Registry Number: 179045-86-4
CAS Name: Anti-(human interleukin 2 receptor) immunoglobulin G1 (human-mouse monoclonal CHI621 g1-chain) disulfide with human-mouse monoclonal CHI621 light chain, dimer
Additional Names: chRFT5
Manufacturers' Codes: SDZ-CHI-621
Trademarks: Simulect (Novartis)
Literature References: Human-murine chimeric monoclonal antibody directed against the interleukin-2 receptor a-chain (IL-2Ra), also known as CD25 antigen, on the surface of activated T cells. Prepn: P. L. Amlot et al., EP 449769 (1991 to Sandoz; Roy. Free Hosp. Sch. Med.). Clinical pharmacology: idem et al., Transplantation 60, 748 (1995). Clinical pharmacokinetics: J. Kovarik et al., ibid. 64, 1701 (1997). Clinical trial in kidney transplantation: B. Nashan et al., Lancet 350, 1193 (1997).
Therap-Cat: Immunosuppressant.
Keywords: Immunosuppressant.
Basswood Batrachotoxin Batyl Alcohol Bayberry Bark BBOT

Basiliximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target CD25
Clinical data
Trade names Simulect
AHFS/ monograph
Pregnancy cat. B (US)
Legal status  ?
Pharmacokinetic data
Half-life 7.2 days
CAS number 152923-56-3 YesY
ATC code L04AC02
DrugBank DB00074
UNII 9927MT646M YesY
Chemical data
Formula C6378H9844N1698O1997S48 
Mol. mass 143801.3 g/mol
 N (what is this?)  (verify)

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor [1] of T cells.[2] It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis Pharmaceuticals product[3] and was approved by the Food and Drug Administration (FDA) in 1998.[4]

It is a chimeric CD25 monoclonal antibody of the IgG1 isotype. It acts as an antagonist at the interleukin-2(IL-2) binding site of the p55 subunit (Tac antigen) of the high affinity IL-2 receptor (CD25) on the surface of the activated T lymphocytes.

Minimum serum level should be 0.2 ug/ml(ELISA) Dose is 20 mg two times 4 days apart generally in an adult. It is given in two doses, the first within 2 hours of the start of the transplant operation and the second 4 days after the transplant. These saturate the receptors and prevent T cells from replication and also from activating the B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.

Like the similar drug daclizumab, basiliximab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of opportunistic infections.[citation needed] In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.

It has been reported that some cases of Lichen Planus have been successfully treated with Basiliximab as an alternative therapy to Cyclosporine, with a dose of 20 mg every 4 days. No short-term side effects have been reported [5]